Sirtuin5 protects colorectal cancer from DNA damage by keeping nucleotide availability

Nat Commun. 2022 Oct 17;13(1):6121. doi: 10.1038/s41467-022-33903-8.

Abstract

In our previous study, we reported that sirtuin5 (SIRT5), a member of the NAD+-dependent class III histone deacetylase family, is highly expressed in colorectal cancer (CRC). Herein we show that SIRT5 knockdown impairs the production of ribose-5-phosphate, which is essential for nucleotide synthesis, resulting in continuous and irreparable DNA damage and consequently leading to cell cycle arrest and enhanced apoptosis in CRC cells. These SIRT5 silencing-induced effects can be reversed by nucleoside supplementation. Mechanistically, SIRT5 activates transketolase (TKT), a key enzyme in the non-oxidative pentose phosphate pathway, in a demalonylation-dependent manner. Furthermore, TKT is essential for SIRT5-induced malignant phenotypes of CRC both in vivo and in vitro. Altogether, SIRT5 silencing induces DNA damage in CRC via post-translational modifications and inhibits tumor growth, suggesting that SIRT5 can serve as a promising target for CRC treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / metabolism
  • DNA Damage*
  • Histone Deacetylases / genetics
  • Humans
  • NAD / metabolism
  • Nucleosides
  • Nucleotides
  • Sirtuins* / genetics
  • Sirtuins* / metabolism
  • Transketolase

Substances

  • Histone Deacetylases
  • NAD
  • Nucleosides
  • Nucleotides
  • Sirtuins
  • Transketolase
  • SIRT5 protein, human